Get the Stockscreener App
180.19
3.14%
5.56
Biogen Inc stock is traded at $180.19, with a volume of 115.94K.
It is up +3.14% in the last 24 hours and down -0.66% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$174.63
Open:
$174.94
24h Volume:
115.94K
Relative Volume:
0.06
Market Cap:
$26.33B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
17.24
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+2.10%
1M Performance:
-0.66%
6M Performance:
+35.55%
1Y Performance:
+17.51%
1-Day Range:
$174.30
$180.75
1-Week Range:
$171.61
$180.75
52-Week Range:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
179.49 | 25.62B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,055.01 | 932.17B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.03 | 492.24B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.55 | 389.14B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
109.59 | 266.67B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
140.50 | 264.62B | 54.45B | 14.42B | 17.15B | 7.333 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen (BIIB) Receives a Hold from Bank of America Securities - The Globe and Mail
Biogen’s Stock Awaits Key Regulatory Catalyst in China - AD HOC NEWS
BIIB: Biogen's LEQEMBI Application Accepted in China - GuruFocus
Eisai and Biogen Announce Acceptance of Biologics License Application for Subcutaneous LEQEMBI® in China - Quiver Quantitative
Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - marketscreener.com
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - Biogen
Biologics License Application for Subcutaneous Formulation - GlobeNewswire
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe - BioSpace
Inside Biotech: A potential paradigm shift in Alzheimer’s therapy — reversal, not just slowing - Proactive Investors
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biosimilars Market is expected to reach US$ 171.79 billion - openPR.com
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
Biogen Inc. $BIIB Stock Position Increased by Cwm LLC - MarketBeat
Biotech pioneer who helped launch Biogen dies at 94 - The Business Journals
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha
Dementia Drugs Market 2025 Outlook: In-Depth Insights, - openPR.com
Ethic Inc. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Spinal Muscular Atrophy Market is expected to reach US$ 20.06 - openPR.com
Recombinant Therapeutic Antibodies And Proteins Market - openPR.com
J. L. Bainbridge & Co. Inc. Cuts Holdings in Biogen Inc. $BIIB - MarketBeat
Vontobel Holding Ltd. Sells 18,760 Shares of Biogen Inc. $BIIB - MarketBeat
Pacer Advisors Inc. Acquires 131,258 Shares of Biogen Inc. $BIIB - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Swedbank AB Grows Stake in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc Gaining or Losing Market Support?Biogen (NASDAQ:BIIB) - Benzinga
Voya Investment Management LLC Has $8.87 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen to Microsoft: 4 Stocks Morningstar Likes for 2026 - TipRanks
Biogen’s Qalsody posts long-term signal in rare genetic ALS - The Pharma Letter
JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results - Nasdaq
Macro Review: How Biogen Inc stock performs in high volatility marketsJuly 2025 Weekly Recap & Daily Oversold Bounce Ideas - moha.gov.vn
Biogen (BIIB): Reassessing Valuation After New QALSODY Data, Pipeline Progress and Renewed Growth Optimism - simplywall.st
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 ExitLearn Why - Yahoo Finance
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts - ts2.tech
Biogen : Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen - marketscreener.com
Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment - GuruFocus
Biogen’s QALSODY shows sustained benefits for SOD1-ALS patients - Investing.com India
Biogen's QALSODY Shows Promising Long-Term Effects on Function and Survival in SOD1-ALS, Published in JAMA Neurology - Quiver Quantitative
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - Biogen
Factor VIII deficiency treatment Market See Incredible Growth 2025-2032 | Baxter, Biogen, Inc., Bayer AG - openPR.com
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers - Barchart.com
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split - ts2.tech
Wedge Capital Management L L P NC Invests $27.02 Million in Biogen Inc. $BIIB - MarketBeat
Fluent Financial LLC Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching - ts2.tech
RBC’s Confidence in Leqembi and MS Pipeline Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen (BIIB) Stock Trades Up, Here Is Why - The Globe and Mail
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open - ts2.tech
Is Biogen Inc. stock a bargain at current levelsJuly 2025 Price Swings & Safe Capital Investment Plans - ulpravda.ru
Biogen (NASDAQ:BIIB) Price Target Raised to $165.00 - MarketBeat
Why Biogen Inc. stock remains undervaluedInsider Buying & Daily Stock Momentum Reports - ulpravda.ru
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth - Pharma Voice
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):